Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HINT1 | P49773 | 6/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314536 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL4386265 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL3422978 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL278167 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL1061031 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL25407962 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13462039 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL14144174 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13296251 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL16809000 | 0.95 | ALDH1A1 (0.63) | ALDH1A1LMNATP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340613-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | IMMUNESENSOR THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-1947092-B1 | Method for producing nucleic acid base having perfluoroalkyl group | TOSOH CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1943251-B8 | A1 ADENOSINE RECEPTOR AGONISTS | GILEAD PALO ALTO INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1943251-B1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20110021748-A1 | Non-Natural Peptides as Models for the Development of Antibiotics | WAYNE STATE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090324708-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF AND A METHOD FOR THE TREATMENT OF RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | UNIVERSIDAD NACIONAL DE QUILMES (AR) | 2009-12-31 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-05-28 | — | — | US | disclosed |
| US-7488720-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1943251-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008055875-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISION THEREOF AND A METHOD FOR THE TREATMENT OF A RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | UNIVERSIDAD NACIONAL DE QUILMES (AR) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007047401-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | CV THERAPEUTICS, INC. | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | ALDH1A1 129/4885LMNA 2001/4885TP53 4125/4885 |
| US-20220340613-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | CGAS, PDE7A, PDE11A | ALDH1A1 3411/4885LMNA 1349/4885TP53 774/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ALDH1A1 1012/4885LMNA 2031/4885TP53 4748/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ALDH1A1 635/4885LMNA 1231/4885TP53 4422/4885 |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | FFAR1, ADORA3, ADORA1 | ALDH1A1 472/4885LMNA 3102/4885TP53 4304/4885 |
| US-20110021748-A1 | Non-Natural Peptides as Models for the Development of Antibiotics | MRPL21, SPOUT1, EMG1 | ALDH1A1 3405/4885LMNA 2736/4885TP53 3042/4885 |
| US-20090324708-A1 | COMPOUND HAVING INHIBITORY ACTIVITY ON A RHO-GTPASE CELL PROTEIN, A PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF AND A METHOD FOR THE TREATMENT OF RHO-GTPASE CELL PROTEIN-MEDIATED CONDITION | RHOA, ARHGDIA, ARHGDIB | ALDH1A1 4493/4885LMNA 4307/4885TP53 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.